European journal of pharmacology, 2010-12, Vol.649 (1), p.210-217
2010
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Neuroprotective effects of chlorogenic acid on scopolamine-induced amnesia via anti-acetylcholinesterase and anti-oxidative activities in mice
- Ist Teil von
- European journal of pharmacology, 2010-12, Vol.649 (1), p.210-217
- Ort / Verlag
- Amsterdam: Elsevier B.V
- Erscheinungsjahr
- 2010
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Chlorogenic acid is a major polyphenolic component of many plants and beverages, and is particularly abundant in coffee. We evaluated the neuroprotective effects of chlorogenic acid on learning and memory impairment induced by scopolamine (0.5 mg/kg, i.p.), a muscarinic antagonist, using the Y-maze, passive avoidance, and Morris water maze tests. The chlorogenic acid significantly improved the impairment of short-term or working memory induced by scopolamine in the Y-maze test, and significantly reversed cognitive impairments in mice as measured by the passive avoidance test. In addition, chlorogenic acid decreased escape latencies in the Morris water maze test. In a probe trial session, chlorogenic acid increased the latency time in the target quadrant in a dose-dependent manner. Ex vivo, chlorogenic acid inhibited acetylcholinesterase activity in the hippocampus and frontal cortex. Chlorogenic acid also decreased malondialdehyde levels in the hippocampus and frontal cortex. In vitro, chlorogenic acid was found to inhibit acetylcholinesterase activity (IC 50 = 98.17 μg/ml) and free radical scavenging activity (IC 50 = 3.09 μg/ml) in a dose-dependent manner. These results indicate that chlorogenic acid may exert anti-amnesic activity via inhibition of acetylcholinesterase and malondialdehyde in the hippocampus and frontal cortex.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0014-2999eISSN: 1879-0712DOI: 10.1016/j.ejphar.2010.09.001Titel-ID: cdi_proquest_miscellaneous_807287467
- Format
- –
- Schlagworte
- Acetylcholine receptors (muscarinic), Acetylcholinesterase, Adult and adolescent clinical studies, Alzheimer Disease - drug therapy, Alzheimer's disease, Amnesia - chemically induced, Amnesia - drug therapy, Amnesia - metabolism, Animals, Antioxidants - administration & dosage, Antioxidants - pharmacology, Antioxidants - therapeutic use, Biological and medical sciences, Chlorogenic acid, Chlorogenic Acid - administration & dosage, Chlorogenic Acid - pharmacology, Chlorogenic Acid - therapeutic use, Cholinesterase Inhibitors - administration & dosage, Cholinesterase Inhibitors - pharmacology, Cholinesterase Inhibitors - therapeutic use, Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases, Disorders of higher nervous function. Focal brain diseases. Central vestibular syndrome and deafness. Brain stem syndromes, Dose-Response Relationship, Drug, Escape Reaction - drug effects, Frontal Lobe - drug effects, Frontal Lobe - enzymology, Frontal Lobe - metabolism, GPI-Linked Proteins - antagonists & inhibitors, Hippocampus - drug effects, Hippocampus - enzymology, Hippocampus - metabolism, Learning and memory, Learning Disorders - chemically induced, Learning Disorders - drug therapy, Learning Disorders - metabolism, Male, Malondialdehyde, Malondialdehyde - metabolism, Medical sciences, Memory, Short-Term - drug effects, Mice, Mice, Inbred ICR, Muscarinic Antagonists - administration & dosage, Muscarinic Antagonists - pharmacology, Muscarinic Antagonists - therapeutic use, Nerve Tissue Proteins - antagonists & inhibitors, Nervous system (semeiology, syndromes), Neurology, Neuroprotective Agents - administration & dosage, Neuroprotective Agents - pharmacology, Neuroprotective Agents - therapeutic use, Organic mental disorders. Neuropsychology, Pharmacology. Drug treatments, Psychology. Psychoanalysis. Psychiatry, Psychopathology. Psychiatry